Pierre Van Damme

I am full professor at the University of Antwerp, Faculty of Medicine and Health Sciences. I chair the research unit VAXINFECTIO, Vaccine & Infectious Disease Institute; VAXINFECTIO is a consortium of three research units within the university: the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and the Centre for the Evaluation of Vaccination (CEV). It is recognized as ‘Centre of Excellence’ of the University of Antwerp and functions as WHO Collaborating Centre for the WHO European Region for the control and prevention of infectious diseases. I am the director of the Centre of the Evaluation of Vaccination. The centre conducts research in 5 main areas: (1) (sero-) epidemiology of infectious diseases; (2) assessment of protective efficacy, safety, immunogenicity, and effectiveness of vaccines; (3) injection and diagnostic device research; (4) kinetics of vaccine-induced antibodies, including passive transfer of maternal antibodies; (5) development of diagnostic tools for infectious diseases. Since 1985 the CEV has conducted more than 300 vaccine trials within the trial unit of Centre for the Evaluation of Vaccination.

I teach infectious diseases and vaccinology at the Faculty of Medicine and Health Sciences as well as in the Faculty of Pharmacy and Biomedical Sciences, University of Antwerp and within master programs of vaccinology at the University of Siena and Florence.

I serve as the executive secretary of the Viral Hepatitis Prevention Board, a group of international experts dealing with topics on prevention and control of viral hepatitis. In 2016 we created a second expert board on HPV, the HPV control and prevention board. My current research projects at the University are focused on the epidemiology and prevention of vaccine-preventable infectious diseases, such as hepatitis A, hepatitis B, diphtheria, pertussis, varicella, rotavirus (in collaboration with NIH, US), measles, HSV, influenza, Ebola, Chikungunya, HPV and polio (in collaboration with the Bill & Melinda Gates Foundation).